BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36494790)

  • 1. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
    BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HPV vaccination and the prevention of genital warts and precancerous lesions-current evidence and evaluation].
    Osmani V; Klug SJ
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 May; 64(5):590-599. PubMed ID: 33851224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of HPV related anogenital diseases in young women in Germany - an analysis of German statutory health insurance claims data from 2012 to 2017.
    Reuschenbach M; Mihm S; Wölle R; Schneider KM; Jacob C; Braun S; Greiner W; Hampl M
    BMC Infect Dis; 2020 Apr; 20(1):297. PubMed ID: 32321435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL
    Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S; Nygård M; Orumaa M; Hansen BT
    Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
    Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
    Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
    Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.
    Thöne K; Horn J; Mikolajczyk R
    BMC Infect Dis; 2017 Aug; 17(1):564. PubMed ID: 28806926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
    Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
    Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
    Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
    BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HPV vaccination: health gains in the Italian female population.
    Marcellusi A
    Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
    Dehlendorff C; Baandrup L; Kjaer SK
    J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic human papillomavirus vaccines: potential for sea change.
    Ferenczy A; Franco EL
    Expert Rev Vaccines; 2007 Aug; 6(4):511-25. PubMed ID: 17669006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.